Lupin Q1 FY27: Sales up 33%, EBITDA up 43%, PAT up 16%

Revenue growth above 20%EBITDA margin expansionResults View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹2385.00

prior close

₹2410.00

announcement price

After-mkt

timing

Nifty Midcap 150market+0.2%-0.8% vs market

Pharmaceuticals peers, median of 167sector+0.3%-0.9% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-1.4

15m

-1.0

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.2-0.8+0.3-0.9

Next day

-3.6+0.7-4.3+0.7-4.3

-4.4+0.6-5.1+0.6-5.1

-5.1+0.9-6.0+0.5-5.6

-5.6+1.0-6.6+1.2-6.9

-6.3+0.5-6.8+0.2-6.5

-6.4+0.2-6.6+0.2-6.6

15d

-8.7+0.8-9.6+1.4-10.1

-11.8-1.1-10.7+2.4-14.2

-15.0-6.3-8.7+1.8-16.8

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin reported Q1 FY27 sales of INR 82,172 Mn, up 33.3% YoY, driven by strong US growth of 42.9% and emerging markets up 51.7%. EBITDA rose 42.8% to INR 25,799 Mn with margin expanding 210 bps to 31.4%. PBT grew 42.5% to INR 20,174 Mn while PAT rose 16% to INR 14,170 Mn due to higher tax outgo. Company remains net cash positive at around INR 28,308 Mn with net debt-equity at minus 0.12.

Likely market impact

Strong quarter with broad-based growth across geographies. Double-digit sales growth, margin expansion, and net cash position are positive for shareholders.